Eddingpharm Gains China Rights To Omega-3 Product in $169 Million Deal

Eddingpharm, a China in-licensing company, signed a deal worth up to $169 million for China rights to Vascepa®, an Amarin prescription omega-3 drug that reduces high levels of triglycerides. The deal includes a $15 million upfront payment; the remaining $154 million consists of development, regulatory and sales-based milestones. In addition, Eddingpharm will also pay tiered double-digit royalties on Vascepa revenues, which are capped in the high teens. Vascepa was granted US approval in 2012. More details.... Stock Symbols: (NSDQ: AMRN) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.